Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement
Rhea-AI Summary
Orchestra BioMed (NASDAQ: OBIO) received a $20 million payment from Medtronic on May 1, 2026, fulfilling a scheduled tranche under their strategic financing agreement and supporting completion of the BACKBEAT Global Pivotal Trial for AVIM Therapy.
Together with a $15 million tranche from Ligand, the company received $35 million in strategic capital; the Medtronic funds were issued as a secured subordinated promissory note convertible to a capped prepaid revenue share tied to FDA approval, with crediting at a low double-digit percentage up to $40 million cumulative.
Positive
- $20M investment received from Medtronic
- $15M Ligand tranche completes $35M strategic capital
- Funding supports completion of the BACKBEAT pivotal trial
Negative
- Medtronic funding issued as a secured subordinated promissory note
- Prepaid revenue share crediting caps at $40M cumulative
News Market Reaction – OBIO
On the day this news was published, OBIO gained 2.49%, reflecting a moderate positive market reaction. This price movement added approximately $6M to the company's valuation, bringing the market cap to $246.11M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 30 | Regulatory designation | Positive | +5.0% | Second FDA Breakthrough Device Designation expanded AVIM Therapy indications. |
| Apr 23 | Clinical data | Positive | -1.4% | HRS 2026 AVIM data presentations showing blood pressure reductions and durability. |
| Mar 12 | Earnings update | Positive | -4.8% | Full-year 2025 results and cash of $106.5M with outlined partnership proceeds. |
| Mar 03 | Conference presentations | Positive | -0.5% | Conference talks on AVIM Therapy’s potential impact on hypertensive heart disease. |
| Feb 19 | Investor conferences | Neutral | -0.5% | Announcement of participation in March institutional investor conferences. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Positive AVIM and corporate updates have often seen muted or negative next-day moves, suggesting a tendency for the stock to underreact or fade good news.
Over the last few months, Orchestra BioMed has focused on AVIM Therapy and pivotal trials. On Apr 30, 2026, an additional FDA Breakthrough Device Designation for AVIM covered over 7.7 million potential U.S. patients and the stock rose 5%. Earlier AVIM data presentations at HRS and other conferences, as well as the 2025 earnings update highlighting $106.5 million in cash and planned strategic proceeds, saw modest to negative reactions. Today’s strategic $20 million Medtronic tranche builds on those collaborations and previously outlined funding expectations.
Key Terms
atrioventricular interval modulation therapy medical
backbeat global pivotal trial medical
pacemaker medical
secured subordinated promissory note financial
u.s. food and drug administration regulatory
hypertensive heart disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Payment fulfills previously disclosed funding commitment of
$20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) evaluating Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic - This payment, together with
$15 million received from Ligand and announced separately, represents a total of$35 million in strategic capital received under previously disclosed agreements
NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a
Robert C. Kowal, M.D., Ph.D., Vice President and General Manager of Cardiac Pacing Therapies within the Medtronic Cardiac Rhythm Management operating unit, commented, “The completion of this investment aligns with the strong clinical trial enrollment we’ve seen in the BACKBEAT Trial for AVIM Therapy. Our collaboration with Orchestra BioMed opens the door to bringing the benefits of pacing therapy to patients with needs beyond traditional rhythm management, offering the potential to treat hypertension and hypertensive heart disease.”
“Medtronic has been an excellent strategic collaborator for the AVIM Therapy program, and this funding further reinforces our long-term alignment under our strategic collaboration agreement,” said David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed. “This funding and the structure of the agreement align capital investments with key regulatory and commercialization objectives as we and Medtronic continue our shared work to complete the BACKBEAT Trial and ultimately deliver AVIM Therapy to pacemaker-indicated patients with uncontrolled hypertension despite medication.”
The
This payment, together with a
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
About AVIM Therapy
AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal trial is evaluating the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted two Breakthrough Device Designations by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.
About Virtue SAB
Virtue SAB is designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™ through a non-coated microporous AngioInfusion™ Balloon that protects the drug in transit to consistently deliver a large liquid dose overcoming certain limitations of drug-coated balloons. SirolimusEFR delivered by Virtue SAB has been shown in published preclinical series involving hundreds of arterial deliveries to achieve sustained tissue levels well above the known required therapeutic tissue concentration for inhibiting restenosis (1 ng/mg tissue) for the entire critical healing period of approximately 30 days. Virtue SAB demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multi-center prospective, independent core lab-adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for specific indications relating to coronary ISR, coronary small vessel disease and peripheral artery disease below-the-knee.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company’s ongoing pivotal trials, realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company’s product candidates, the potential benefits of Breakthrough Device Designation, and the ability of the Company’s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company’s commercial product candidates and ongoing regulation of the Company’s product candidates, if approved; the timing of, and the Company’s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 12, 2026.
The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk
Orchestra BioMed
kkirkellis@orchestrabiomed.com
